Fast Track Designation (FTD) is designed to accelerate the development and expedite the review of therapies with potential to address unmet medical needs for a serious or life-threatening condition
TSHA-102 has also received Orphan Drug and Rare Pediatric Disease designations from the United States (U.S.) Food and Drug Administration (FDA) and has been granted Orphan Drug designation from the European Commission
https://finance.yahoo.com/news/taysha-gene-therapies-announces-fast-120000035.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.